THU0400 Relationship between Health Quality of Life and Other Indicators in Patients with Axial Spondyloarthritis

Background Axial spondyloarthritis (AxSpA) is an inflammatory disease that mainly affects the spine. As the disease progresses, there is a reduction of quality of life (QOL) in patients due to loss of mobility and function, and also by episodes of inflammation and stiffness (disease activity). Objectives To Analyze relationship between QOL of patients with AxSpA and other commonly used indicators in assessing these patients. Methods 100 patients with AxSpA (67% male, age 48.38±11.05, disease duration 14.37±10.74, HLAB27 + 85%) were included. QOL of patients was assessed by the Ankylosing Spondylitis Quality of Life index (ASQoL). Mobility was evaluated by conventional metrology and by a new motion capture system (UCOTrack) and UCOASMI as its metrological index [1]. PRO questionnaries were completed to evaluate activity, function and overall status. Structural damage was scored by mSASSS index. To analyze relationship, Spearman tests, ANOVA and multiple linear regression were performed. Results ASQoL showed statistically significant correlations with BASFI, BAS-G, ASDAS and UCOASMI. No significant correlations between QOL and structural damage, neither B27+, or having nr-AxSpA were found. Table shows results groupped by sex, B27, duration, nr-AxSpA (mSASSS <5 Duration>5 years) high activity level and poor mobility with statistical significance. Variables that were independently associated with ASQOL, in a multivariable linear regresion, were gender (p=0.027), BASDAI (p=0.008) and BASFI (p<0.001) R2 =0.676. Repeating this analysis, but including mobility measures obtained by motion capture, variables that were independently associated with ASQoL were BASDAI (p=0.000) lateral flexion defined by the position of shoulders and hips (p=0.004) and tilt of C7-L4 (p=0.023) R2 =0.609. Table 1 Total Male/Female B27+/B27− Duration >10/Duration <10 AxSpA/nr-AxSpA ASDAS >2.1/ASDAS <2.1 UCOASMI >4/UCOASMI <4 Patients (n) 100 67/33 85/15 60/40 72/28 66/34 58/42 ASQoL 4.0 (2.8) 3.6 (2.8)/4.8 (2.7)* 3.8 (2.7)/4.8 (3.4) 4.0 (2.65)/3.8 (3.12) 4.0 (2.7)/3.9 (2.9) 5.2 (2.6)/1.9 (1.9)** 5.0 (2.6)/2.6 (2.3)** ASDAS 2.6 (1.0) 2.5 (1.0)/2.8 (1.1) 2.5 (1.0)/2.9 (1.2) 2.7 (1.01)/2.5 (1.20) 2.6 (1.0)/2.4 (1.0) 3.2 (0.7)/1.4 (0.4)** 3.0 (1.0)/1.8 (0.7)** BASFI 3.8 (2.8) 3.7 (3.0)/4.0 (2.6) 3.7 (2.8)/4.3 (3.3) 4.0 (2.94)/3.3 (2.86) 4.0 (2.8)/3.3 (2.9) 5.2 (2.6)/1.6 (1.6)** 5.3 (2.6)/1.8 (1.7)** BASG 4.7 (2.6) 4.3 (2.5)/5.3 (2.7) 4.7 (2.6)/4.6 (2.5) 4.6 (2.5)/4.6 (2.8) 4.7 (2.6)/4.5 (2.5) 6.1 (2.0)/1.9 (1.2)** 5.5 (2.4)/3.6 (2.4)** UCOASMI 4.7 (1.8) 4.8 (2.0)/4.6 (1.4) 4.7 (1.8)/4.5 (2.0) 5.1 (1.9)/3.9 (1.4)** 5.0 (1.9)/3.8 (1.3)** 5.3 (1.6)/4.1 (1.9)* 5.9 (1.5)/3.1 (0.6)** mSASSS 14.4 (16.3) 18.1 (18.7)/6.9 (3.9)** 14.4 (16.6)/14.7 (15.9) 17.3 (17.7)/8.3 (7.6)** 18.7 (17.4)/3.3 (1.5)** 16.2 (17.3)/16.7 (19.2) 19.6 (19.5)/7.2 (5.1)** * p<0.05, ** p<0.001. Conclusions QOL in AxSpA is influenced by the activity of the disease, and by decreased mobility. Women perceive a lower QOL. The best measure related to QOL is lateral bending. Improving patient mobility through exercise and finding appropriate treatment to decrease disease activity, you can improve QOL of patients with AxSpA. References Garrido-Castro JL, et al. Validation of a new objective index to measure spinal mobility: the University of Cordoba Ankylosing Spondylitis Metrology Index (UCOASMI). Rheumatol Int. 2014 Mar;34(3):401–6 Disclosure of Interest None declared